Network pharmacology and metabolomics analyses reveal dihydroberberine’s involvement in multiple biochemical pathways, including PI3K-Akt and MAPK, underpinning its therapeutic action.
Preclinical and clinical pilot studies suggest potential roles of dihydroberberine in metabolic syndrome management and as an adjunct in asthma therapy.
Despite encouraging pharmacokinetic profiles, clinical efficacy data remain limited, warranting larger, longer-term trials to define its therapeutic scope and safety.
